Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Potent Anti-Myeloma Activity of the TOPK inhibitor OTS514 in Pre-Clinical Models

ABSTRACT: Evaluation of gene expression upon treatment with OTS514 in combination with existing thereapeutics in H929 cells

ORGANISM(S): Homo sapiens

PROVIDER: GSE128251 | GEO | 2019/11/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.

Project description: Not available

| S-EPMC6943155 | biostudies-literature

Potent Anti-Myeloma Activity of the TOPK inhibitor OTS514 in Pre-Clinical Models

Project description:Potent Anti-Myeloma Activity of the TOPK inhibitor OTS514 in Pre-Clinical Models

| PRJNA526885 | ENA

The FHP01 DDX3X Helicase Inhibitor Exerts Potent Anti-Tumor Activity In Vivo in Breast Cancer Pre-Clinical Models.

Project description: Not available

| S-EPMC8507746 | biostudies-literature

HDAC and aminopeptidase inhibitor treatment of myeloma cells

Project description:H929 human myeloma cells were exposed to aminopeptidase inhibitor (CHR-2797), HDAC inhibitor (CHR-3996), or a combinaion of the two agents, for 24 hours. Following this treatment RNA was extracted and microarrays used to determine gene expression changes.

2014-01-24 | GSE20405 | GEO

HDAC and aminopeptidase inhibitor treatment of myeloma cells

2014-01-24 | E-GEOD-20405 | biostudies-arrayexpress

Treatment of myeloma cell lines with the bromodomain inhibitor I-BET151

Project description:KMS12BM and H929 myeloma cells were treated in vitro with either I-BET151 1uM or vehicle (DMSO) for 6 hours (n=3 independent experiments for each cell line). Total RNA was extracted from H929 and KMS12BM cells using the RNeasy Mini kit (Qiagen). Genomic DNA contamination was eliminated using columns (Qiagen) and DNAase digestion. The extracted RNA was quantified in a Nanodrop, while purity and integrity was confirmed on an Agilent 2100 Bioanalyser with RNA Nano Chips. cDNA was produced from 150ng total RNA input, using the Ambion WT Expression Kit. The cDNA was then fragmented and labelled using the GeneChip WT Terminal Labelling Kit (Affymetrix) and hybridised on Human Gene ST1.0 Arrays (Affymetrix) on a GeneChip Fluidics Station 450. The arrays were scanned in a GeneChip Scanner 3000 7G with autoloader.

2013-12-22 | E-MTAB-2122 | biostudies-arrayexpress

Pre-clinical models of genetically heterogeneous multiple myeloma reveal immune evasion mechanisms and predict clinical immunotherapy outcomes

Project description:The historical lack of pre-clinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers advancing therapeutic discoveries. To circumvent this limitation, we have generated fifteen genetically diverse models that developed bone marrow tumors fulfilling MM pathogenesis. Transcriptomic analysis of tumor plasma cells revealed that MYC activation regulates time to progression. Bone marrow cell composition analysis classified myeloma tumors into immune-cold and inflamed categories, which condition immune checkpoint blockade responses in mouse multiple myeloma models.

2023-03-17 | GSE205644 | GEO

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.

Project description: Not available

| S-EPMC3049593 | biostudies-literature

Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.

Project description: Not available

| S-EPMC5740082 | biostudies-literature

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Project description: Not available

| S-EPMC2200918 | biostudies-literature